A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Eligibility Criteria

• * At least 18 years of age, or country defined local legal age
• * Demonstrated adequate organ function at screening
• * Life expectancy \>12 weeks as determined by the Investigator
• * Female and male participants of childbearing potential who are sexually active must agree to use highly effective methods of contraception
• * Participants must have histologically confirmed locally advanced, recurrent, or metastatic solid tumor malignancies that cannot be treated with curative intent (surgery or radiotherapy), with the exception of the neoadjuvant cohorts
• * Part 1 and Part 2: Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
• * Part 3 and Part 4: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• * Participants who have undergone treatment with anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte-associated protein (CTLA-4) antibody must have a washout of at least 4 weeks from the last dose and evidence of disease progression per investigator assessment before Cycle 1 Day 1 (C1D1) with the exception of the neoadjuvant cohorts
• * Participants who have previously received an immunotherapy prior to C1D1 must have any immune-related toxicities resolved to ≤Grade 1 or baseline (prior to the immunotherapy) to be eligible, with the exception of participants on well controlled physiologic endocrine replacement
• * Part 3: Neoadjuvant cohorts: participants must have completely resectable disease
• * Symptomatic central nervous system metastases and/or carcinomatous meningitis
• * Active autoimmune diseases, regardless of need for immunosuppressive treatment, with the exception of participants well controlled on physiologic endocrine replacement
• * Any uncontrolled bacterial, fungal, viral, or other infection
• * Significant cardiac disease
• * A marked clinically significant baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>480 ms) \[CTCAE Grade 1\]) using Fridericia's QT correction formula
• * Positive for human immunodeficiency virus (HIV) or has known active hepatitis B or C infection
• * Known hypersensitivity to any study treatment(s) used in the specific study part/cohort
• * Part 3, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, and Neoadjuvant Melanoma: Participants who have been previously treated with IL-2 or IL-2 variants (all participants), or TLR agonist
• * Systemic immunosuppressive treatment with the exception for patients on corticosteroid taper (for example, for chronic obstructive pulmonary disease exacerbation).
• * Vaccination with live, attenuated vaccines within 4 weeks of C1D1
• * Treatment with any other anti-cancer systemic treatment (approved or investigational) or radiation therapy within 4 weeks of C1D1
• * Part 3: Other active malignancies within the last 2 years
• * Women who are breastfeeding or have a positive serum pregnancy test during screening